Abstract LB248: Development of organotypic patient-derived ovarian cancer model for therapy testing
View Full Paper
Ask AI
Bookmark
Share
Key Points
The aim is to develop a comprehensive organotypic model that mimics ovarian cancer characteristics for therapy testing.
Utilized tumor sections from five high-grade serous ovarian carcinoma donors.
Established cultures using OrganoPlate Graft UF platform with tumor tissue, cancer-associated fibroblasts, and endothelial cells.
Characterized models through immunostaining and cytokine analysis.
Models exhibited varying tumor-stroma ratios and immune infiltration levels.
Chemotherapy treatments showed different responses across donors, revealing effects on tumor clusters and surrounding supportive cells.
The 3D model demonstrated enhanced chemoresistance compared to conventional 2D cell lines.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Develops a patient-derived model to evaluate therapy responses in ovarian cancer, suggesting enhanced predictive capabilities over traditional methods.